| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
24,911,000 |
| Market
Cap: |
3.86(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$87.45 - $180.42 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Krystal Biotech is a clinical-stage biotechnology company focused on the development of gene therapies to improve the lives of patients living with rare diseases. Co. has developed a gene delivery platform that enables off-the-shelf treatments for serious dermatology and respiratory diseases. Co.'s platform consists of a patented, engineered viral vector derived from the herpes simplex virus type 1 (HSV-1) that it has optimized for local and repeat gene transfer to epithelial cells. Co.'s main product candidate is Beremagene geperpavec (B-VEC), which is for the treatment of dystrophic epidermolysis bullosa, a rare skin disease caused by missing or mutated mutated type VII collagen protein.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
120,587 |
223,087 |
589,015 |
1,054,015 |
| Total Sell Value |
$20,277,416 |
$31,168,998 |
$73,717,148 |
$112,293,066 |
| Total People Sold |
3 |
3 |
5 |
6 |
| Total Sell Transactions |
7 |
12 |
26 |
67 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Krishnan Suma |
President, R&D |
• • • |
2023-12-11 |
4 |
AS |
$104.41 |
$2,641,628 |
I/I |
(25,000) |
1,634,338 |
|
53% |
|
| Krishnan Suma |
President, R&D |
• • • |
2023-12-11 |
4 |
AS |
$104.26 |
$2,641,663 |
D/D |
(25,000) |
1,574,206 |
|
53% |
|
| Krishnan Krish S |
President and CEO |
• • • |
2023-12-11 |
4 |
AS |
$104.26 |
$2,641,663 |
I/I |
(25,000) |
1,574,206 |
|
53% |
|
| Krishnan Krish S |
President and CEO |
• • • |
2023-12-11 |
4 |
AS |
$104.41 |
$2,641,628 |
D/D |
(25,000) |
1,634,338 |
|
53% |
|
| Krishnan Krish S |
President and CEO |
• • • |
2023-09-11 |
4 |
AS |
$125.23 |
$3,180,841 |
I/I |
(25,000) |
1,599,206 |
|
0% |
|
| Krishnan Krish S |
President and CEO |
• • • |
2023-09-11 |
4 |
AS |
$125.23 |
$3,180,839 |
D/D |
(25,000) |
1,659,338 |
|
0% |
|
| Krishnan Suma |
President, R&D |
• • • |
2023-09-11 |
4 |
AS |
$125.23 |
$3,180,839 |
I/I |
(25,000) |
1,659,338 |
|
0% |
|
| Krishnan Suma |
President, R&D |
• • • |
2023-09-11 |
4 |
AS |
$125.23 |
$3,180,841 |
D/D |
(25,000) |
1,599,206 |
|
0% |
|
| Orth Andrew C. |
Chief Commercial Officer |
• – – |
2023-06-09 |
4 |
AS |
$128.10 |
$1,607,635 |
D/D |
(12,500) |
100 |
|
-12% |
|
| Orth Andrew C. |
Chief Commercial Officer |
• – – |
2023-06-09 |
4 |
OE |
$63.55 |
$794,375 |
D/D |
12,500 |
12,600 |
|
- |
|
| Janney Daniel |
Director |
– • – |
2023-06-09 |
4 |
S |
$128.53 |
$2,438,223 |
I/I |
(18,935) |
107,362 |
|
12% |
|
| Janney Daniel |
Director |
– • – |
2023-06-08 |
4 |
S |
$127.86 |
$3,979,854 |
I/I |
(31,065) |
126,297 |
|
9% |
|
| Krishnan Suma |
President, R&D |
• • • |
2023-05-31 |
4 |
S |
$116.00 |
$2,905,977 |
I/I |
(25,000) |
1,684,338 |
|
1% |
|
| Krishnan Suma |
President, R&D |
• • • |
2023-05-31 |
4 |
S |
$115.98 |
$2,903,912 |
D/D |
(25,000) |
1,624,206 |
|
1% |
|
| Krishnan Krish S |
President and CEO |
• • • |
2023-05-31 |
4 |
S |
$115.98 |
$2,903,912 |
I/I |
(25,000) |
1,624,206 |
|
1% |
|
| Krishnan Krish S |
President and CEO |
• • • |
2023-05-31 |
4 |
S |
$116.00 |
$2,905,977 |
D/D |
(25,000) |
1,684,338 |
|
1% |
|
| Romano Kathryn |
Chief Accounting Officer |
• – – |
2023-05-22 |
4 |
AS |
$105.80 |
$2,725,992 |
D/D |
(25,000) |
12,556 |
|
-1% |
|
| Romano Kathryn |
Chief Accounting Officer |
• – – |
2023-05-22 |
4 |
OE |
$52.26 |
$1,447,625 |
D/D |
25,000 |
25,056 |
|
- |
|
| Romano Kathryn |
Chief Accounting Officer |
• – – |
2023-05-19 |
4 |
AS |
$95.04 |
$2,702,123 |
D/D |
(28,428) |
12,556 |
|
23% |
|
| Romano Kathryn |
Chief Accounting Officer |
• – – |
2023-05-19 |
4 |
OE |
$52.26 |
$1,306,500 |
D/D |
25,000 |
28,484 |
|
- |
|
| Janney Daniel |
Director |
– • – |
2023-05-19 |
4 |
AS |
$95.02 |
$4,751,185 |
I/I |
(50,000) |
157,362 |
|
23% |
|
| Janney Daniel |
Director |
– • – |
2023-05-09 |
4 |
AS |
$90.74 |
$1,551,579 |
I/I |
(17,100) |
207,362 |
|
29% |
|
| Janney Daniel |
Director |
– • – |
2023-04-19 |
4 |
AS |
$90.32 |
$713,493 |
I/I |
(7,900) |
224,462 |
|
40% |
|
| Krishnan Suma |
President, R&D |
• • • |
2023-04-17 |
4 |
AS |
$85.55 |
$2,191,211 |
I/I |
(25,000) |
1,713,688 |
|
41% |
|
| Krishnan Suma |
President, R&D |
• • • |
2023-04-17 |
4 |
AS |
$85.55 |
$2,191,213 |
D/D |
(25,000) |
1,649,206 |
|
41% |
|
134 Records found
|
|
Page 2 of 6 |
|
|
3.98 (2.5%) 
